In a report released yesterday, Davide Longo from TP ICAP MIDCAP reiterated a Buy rating on Svas Biosana S.p.A. (SVS – Research Report), with a price target of €12.40.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Davide Longo has given his Buy rating due to a combination of factors that highlight Svas Biosana S.p.A.’s strong financial performance and strategic positioning. The company reported a record revenue for FY 2024, driven by the robust growth in its medical device distribution business in Eastern Europe, which has significantly contributed to the expansion of its operating margins. The strategic acquisitions in Serbia have further solidified the company’s presence in this high-growth region, underscoring the effectiveness of its expansion strategy.
Additionally, the company’s divisions, Mark Medical and Bormia, have shown impressive revenue growth, reinforcing the success of Svas Biosana’s focus on high-demand medical devices. Despite some declines in other divisions due to strategic repositioning, the overall financial health remains strong, with an improved EBITDA margin and a notable increase in net income. The company’s ability to manage costs effectively and benefit from easing raw material prices further supports the positive outlook. These factors collectively justify the Buy recommendation with a target price of €12.4.
According to TipRanks, Longo is ranked #3000 out of 9350 analysts.